To optimize therapies for patients using a patient-centric technology-driven clinical research approach.
Transforming medical research with patient-centricity.
I have always been interested in how to disrupt the system of basic and clinical medical research in order to achieve better outcomes for people afflicted with disease. For me, it started with building systems that incorporated biomarker discovery and patient selection strategies to better predict which patients would truly benefit from which therapies, keeping in mind most patients and practitioners are not in treatment at the top academic medical centers. The most critical part of clinical research is the end game; unfortunately, most drugs underperform once they are broadly launched into the market.
How do we understand patient needs and deliver solutions that work for them, their lifestyle, within their health systems?
This results from many things, but much of it is due to the limitations in our health care systems, and lack of attention to building implementation models and solutions in diverse real-world care settings. The most critical part of clinical research is the end game- truly how do we understand patient needs and deliver to them solutions that work for them in their lives, in their health systems. The advent and ubiquitous nature of mobile technology now give us the opportunity to understand the patient experience, incorporate that into better care management practice focused on patient outcomes and to build this knowledge into how we design, develop and bring drugs to the market. Our company was founded on capturing real-world evidence to drive smarter health care interventions.
Founder and CEO, MyOwnMed
Vicki Seyfert-Margolis, Ph.D.
Vicki Seyfert-Margolis, Ph.D. founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family-based co-management of health. Previously, Dr. Seyfert-Margolis was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science.
Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation.
Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs.
Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.
Molly Muldoon
Molly Muldoon is the Chief Administrative Officer at My Own Med, Inc. Previously she served as the Vice President of Public Policy for Onyx Pharmaceuticals. She was responsible for establishing and leading key policy and regulatory positions for the company.
Ms. Muldoon was formerly the Federal Drug Administration’s (FDA) Chief of Staff, overseeing the operations and liaising with senior leadership across the federal government on key issues including the Affordable Care Act, Deepwater Horizon, food safety regulations, and food borne outbreaks. As a seasoned leader in organizational change and strategic planning, she has served as the Chief Administrative Officer for both the National Restaurant Association and AARP Services. During her respective tenures she guided the organizations through organizational re-alignments, strategic planning efforts and assisted with identifying increased efficiency opportunities and expanding public outreach activities.
Ms. Muldoon served in the Clinton Administration for both terms at the White House and the Department for Health and Human Services (HHS). Her roles included Special Assistant to the White House Chief of Staff, Special Assistant to Counselor for the President, and finally Special Assistant to the Deputy Secretary of HHS.
Trang Gisler
Trang Gisler is certified as Project Management Professional and Certified Clinical Research Professional. She is an executive-level Program Manager with over 10 years of scientific/technical, IT and business management experience in both the public and private sector with key emphasis on research & development, clinical trials, vaccine and program managements.
She was the Director of Program Management and Operation for the Office of the Commissioner/Office of Chief Scientist at the Food and Drug Administration, managing multiple million-dollar science portfolios. Prior to the FDA, she worked at the Department of Health and Human Services and the Department of Defense as the Project Officer managing over multimillion-dollar science programs.
Preceding this, she served as Associate Director for the Tolerance Assay Group at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, she managed the operation of 20 centralized laboratory facilities, and the execution of biomarker discovery studies for over 25 Phase II clinical trials.
She is a customer-focused executive with the unique ability to lead the entire business spectrum, providing strategic business management and hands-on technical leadership to cross-functional teams and external customers.